Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 0.84 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.84 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.84 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.84 |
| ▸ | PGR | P06401 | 1/20 | 0.84 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | RXRA | P19793 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.84 |
| ▸ | CCKAR | P32238 | 1/20 | 0.84 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.84 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL1786786 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL5056806 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL29380299 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL31002987 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147655 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL556763 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41503 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41502 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL41663 | 1.00 | CYP2C9 (1.00) | CYP2C9KDM4EALDH1A1LMNACYP1A2 | |
| Fluvastatin SCHEMBL1147661 | 0.99 | CYP2C9 (0.98) | CYP2C9KDM4EALDH1A1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330435-B1 | CRYSTALLINE FORMS OF FLUVASTATIN SODIUM | CIBA SC HOLDING AG (CH) | 2005-08-24 | — | — | EP | claimed |
| US-6858643-B2 | Crystalline forms of Fluvastatin sodium | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-02-22 | — | — | US | claimed |
| US-20030125569-A1 | Use of packing strip as a holographic data carrier | CIBA SPECIALTY CHEMICALS CORP. | 2003-07-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125569-A1 | Use of packing strip as a holographic data carrier | HMGCR, HSD3B1, HSD3B2 | HMGCR 1/4885CYP2C9 17/4885KDM4E 3252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.